4D Molecular Therapeutics, Inc. (FDMT) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	92.0M	85.2M	37.0K	20.7M	3.1M
Cost of Revenue	53.4M	7.6M	141.3M	97.1M	80.3M
Gross Profit	38.6M	77.6M	(141.3M)	(76.4M)	(77.1M)
Operating Expenses
R&D Expense	240.3M	195.7M	141.3M	97.1M	80.3M
SG&A Expense	48.8M	49.1M	46.6M	36.5M	32.9M
General & Admin Expense	48.8M	49.1M	46.6M	36.5M	32.9M
Selling & Marketing Expense	—	—	—	—	—
Other Expenses	(53.4M)	(7.6M)	(141.3M)	(97.1M)	(80.3M)
Total Operating Expenses	235.8M	237.1M	46.6M	36.5M	32.9M
Cost and Expenses	289.1M	244.8M	187.9M	133.6M	113.2M
Operating Income (EBIT)	(197.1M)	(159.5M)	(187.8M)	(112.9M)	(110.0M)
Non-Operating
Interest Income	18.2M	19.5M	27.1M	12.2M	2.6M
Interest Expense	—	—	—	—	—
Net Interest Income	18.2M	19.5M	27.1M	12.2M	2.6M
Other Non-Op Income/Expense	17.9M	19.4M	27.0M	12.0M	2.5M
Non-Operating Income (excl Interest)	(5.0M)	(19.4M)	(27.0M)	(12.0M)	(2.5M)
EBT (Pre-Tax Income)	(179.2M)	(140.1M)	(160.9M)	(100.8M)	(107.5M)
Income Tax Expense	—	—	—	—	—
Bottom Line
Net Income	(179.2M)	(140.1M)	(160.9M)	(100.8M)	(107.5M)
Earnings from Cont. Ops	(179.2M)	(140.1M)	(160.9M)	(100.8M)	(107.5M)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	(179.2M)	(140.1M)	(160.9M)	(100.8M)	(107.5M)
Per Share
Basic EPS	($2.72)	($2.42)	($2.98)	($2.58)	($3.12)
Diluted EPS	($2.72)	($2.42)	($2.98)	($2.58)	($3.12)
Revenue Per Share	$1.31	$1.47	$0.00	$0.53	$0.10
Shares
Basic Shares Outstanding	70.3M	57.9M	53.9M	39.1M	32.4M
Diluted Shares Outstanding	70.3M	57.9M	53.9M	39.1M	32.4M
Profitability Metrics
EBITDA	(184.9M)	(132.5M)	(154.2M)	(96.6M)	(105.1M)
D&A	7.4M	7.6M	6.7M	4.2M	2.4M
EBIT	(192.1M)	(140.1M)	(160.9M)	(100.8M)	(107.5M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026